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Abstract
!
Background: Official guideline “indications and
methods of hysterectomy” to assign indications
for the different methods published and coordi-
nated by the German Society of Gynecology and
Obstetrics (DGGG), the Austrian Society of Gyne-
cology and Obstetrics (OEGGG) and the Swiss So-
ciety of Gynecology and Obstetrics (SGGG). Be-
sides vaginal and abdominal hysterectomy, three
additional techniques have been implemented
due to the introduction of laparoscopy. Organ-
sparing alternatives were also integrated.
Methods: The guideline group consisted of 26 ex-
perts from Germany, Austria and Switzerland.
Recommendations were developed using a struc-
tured consensus process and independent mod-
eration. A systematic literature search and quality
appraisal of benefits and harms of the therapeutic
alternatives for symptomatic fibroids, dysfunc-
tional bleeding and adenomyosis was done
through MEDLINE up to 6/2014 focusing on sys-
tematic reviews and meta-analysis.
Results: All types of hysterectomy led in studies
to high rates of patient satisfaction. If possible,
vaginal instead of abdominal hysterectomy
should preferably be done. If a vaginal hysterec-
tomy is not feasible, the possibility of a laparo-
scopic hysterectomy should be considered. An ab-
dominal hysterectomy should only be done with
a special indication. Organ-sparing interventions
also led to high patient satisfaction rates, but con-
tain the risk of symptom recurrence.
Conclusion: As an aim, patients should be en-
abled to choose that therapeutic intervention for
their benign disease of the uterus that convenes
best to them and their personal life situation.
Zusammenfassung
!
Hintergrund: Offizielle Leitlinie, publiziert und
koordiniert von der Deutschen Gesellschaft für
Gynäkologie und Geburtshilfe (DGGG), der Öster-
reichischen Gesellschaft für Gynäkologie und Ge-
burtshilfe (OEGGG) und der Schweizerischen
Gesellschaft für Gynäkologie und Geburtshilfe
(SGGG). Durch die Einführung laparoskopischer
Operationen wurde die vaginale und abdominale
Hysterektomie um 3 weitere Techniken ergänzt.
Um die Indikationsfelder abzugrenzen, wurde die
Leitlinie „Indikation und Methodik der Hyster-
ektomie bei benignen Erkrankungen“ initiiert. Or-
ganerhaltende Therapiealternativen wurden
ebenfalls integriert.
Methode: Die Leitlinie wurde durch ein reprä-
sentatives Gremium von 26 Experten aus
Deutschland, Österreich und der Schweiz unter
strukturierter unabhängiger Moderation im Kon-
sens erstellt. Die systematische Literatursuche
und ‑bewertung zu Nutzen und Schaden der The-
rapiealternativen bei symptomatischem Uterus
myomatosus, funktionellen Blutungsstörungen
und Adenomyosis sowie ein Vergleich der Hyster-
ektomieverfahren erfolgte bis 06/2014 in der Da-
tenbank MEDLINE mit Fokus auf aggregierter Evi-
denz.
Ergebnisse: Alle Formen der Hysterektomie sind
in Studien mit einer hohen Zufriedenheit der Pa-
tientinnen verbunden. Der vaginalen Hysterekto-
mie soll gegenüber der abdominellen, wennmög-
lich, der Vorzug gegeben werden. Ist die vaginale
Hysterektomie nicht möglich, sollte die Möglich-
keit einer laparoskopischen Hysterektomie ge-
prüft werden. Die abdominale Hysterektomie
sollte nur bei gesonderter Indikation durch-
geführt werden. Für die organerhaltenden Alter-
nativen wurde ebenfalls ein hoher Zufrieden-
heitsgrad festgestellt, allerdings können bei Belas-
sen des Uterus Rezidive auftreten.
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Purpose and objectives
This guideline concerns hysterectomy performed in patients with
benign diseases. It aims to examine the entire range of surgical
procedures as well as the associated context in order to permit
optimal treatment of women in each case. The guideline presents
and evaluates the individual indication areas, describes the hys-
terectomy routes, evaluates the advantages and disadvantages of
individual surgical techniques and presents possible alternatives.
The guideline aims to provide a basis that women can use to ob-
tain in-depth information in order to make a decision about the
treatment plan in consultation with their doctor based on their
knowledge of the advantages and disadvantages of the specific
procedure and of the effects of the operation on their quality of
life. In these times of increasing cost pressure in the health care
system, it is also essential to include this aspect in the considera-
tions.
Targeted patients
Patients with an equivocal indication for hysterectomy and pa-
tients who have undergone a hysterectomy.
Target audience
The guideline addresses members of the health care profession
involved in performing this surgical procedure. A medical back-
ground is required to understand this guideline.Neis KJ et al. Indications and Route… Geburtsh Frauenheilk 2016; 76: 350–364This guideline is aimed at the following groups of people:
" gynecologists in private practice
" gynecologists working in a clinical setting
" nursing professionals
" the cooperating partners of the medical profession (e.g. health
care professionals, payers)
" the patients concerned and their personal setting (partners,
etc.)
" the general public, in order to provide it with information
about sound medical approaches
Period of validity
The validity of this guideline was confirmed by the chairpersons/
heads of the participating medical societies/organizations/asso-
ciations and by the head of the DGGG and the DGGG Guideline
Commission in April 2015, thereby also confirming the entire
contents of the guideline. This guideline is valid until April 30,
2020. This period of validity was estimated based on the contents
of the guideline. If need be, the guideline can be updated before it
has expired; if the guideline is still considered to represent the
current state of knowledge, its period of validity can be extended.III Guideline
1 Methodology
1.1 Principles
The methodology for the compilation of this guideline is pre-
scribed by the classification assigned to the guideline. The AWMF
Guidance Manual and Rules for Guideline Development (Version
1.0) sets out the rules for classifying guidelines. Guidelines are
differentiated into lowest (S1), moderate (S2) and highest (S3)
class. The lowest class of guideline is defined as consisting of a
set of recommendations for action compiled by a non-represen-
tative group of experts. In 2004 the S2 class was divided into two
subclasses: S2e (evidence-based) and S2k (consensus-based). The
highest class (S3) combines both approaches.
This guideline is classified as S3.
1.2 Literature search
The following literature databases were searched:
" Cochrane Menstrual Disorders and Subfertility Group special-
ized register of controlled trials
" Central
" MEDLINE
" Embase
" Biological Abstracts
" The National Research Register
The following keywords were used for the search:
" hysterectomy CRT
" hysterectomy
" vaginal
" abdominal
" LAVH
" LASH
" TLH
" myoma
" endometriosis
" adenomyosis
" descensus
" incontinence
Table 3 Classification of consensus strength.
Symbol Consensus strength Agreement in percent
+++ Strong consensus Agreement of
> 95% of the participants
++ Consensus Agreement of
> 75–95% of the participants
+ Majority agreement Agreement of
> 50–75% of the participants
– No consensus Agreement of
< 50% of the participants
353Guideline" complications
" quality of life
The search encompassed the period from January 1990 to No-
vember 2011. In addition, MEDLINE was specifically searched
with regard to certain questions.
In order to achieve a transparent and up-to-date evidence base,
an updated literature search was performed in MEDLINE (via
PubMed) in 2013–2014 on the following topics:
" comparison of hysterectomy routes
" comparison of hysterectomy to uterine artery embolization or
myomectomy for symptomatic uterine fibroids
" comparison of hysterectomy and drug therapy for uterine fib-
roids, dysfunctional menstrual disorders or adenomyosis.
The results of the literature search were included in the current
version of the guideline.
1.3 Evidence tables
1.3.1 Evidence grading based on the Oxford Centre
for Evidence-Based Medicine levels of evidence
To evaluate the evidence (levels 1 to 5), the Oxford Centre for Evi-
dence-Based Medicine classification system was used in its most
recent version published in 2009 as Level of Evidence (LoE).
1.4 Recommendation grading
Pure evidence grading of a guideline at S2e/S3 level based on the
Oxford classification can be translated into a grade of recommen-
dation (GR) for a guideline. This symbolic recommendation level
is divided into three gradations with various degrees of linguistic
expression (l" Table 2).Table 2 Grading of recommendations.
Symbols Description of binding nature Expression
A Strong recommendation with
highly binding character
must (soll)/
must not (soll nicht)
B Regular recommendation with
moderately binding character
should (sollte)/
should not (sollte nicht)
0 Open recommendation with
limited binding character
may (kann)/
does not need to
(kann nicht)The classification of “Recommendations” presented above corre-
sponds to both the evaluation of evidence and the clinical rele-
vance of the studies on which they are based and their scope/fac-
tors not listed in the grading of the evidence, such as the selection
of patient cohort, intention-to-treat or per-protocol outcome
analyses, medical or ethical action toward the patient, country-
specific applicability, etc. Conversely, a strong, moderate or weak
level of evidence can lead to strong, regular or open recommen-
dations in a related linear fashion. The only level that permits
both an upward and downward classification is the moderate
evidence level, in which a translation into level A or level 0 is pos-
sible. In special exceptional cases, converting the highest evi-
dence level into the weakest/an open recommendation or vice
versa must be explained in the background text.
" Strong evidence level→ Grade A or Grade B recommendation
" Moderate evidence level → Grade A or Grade B or Grade 0 rec-
ommendation
" Weak evidence level→ Grade B or Grade 0 recommendation1.5 Statements
If statements by specialists are included in this guideline that are
not intended as recommendations for action, but rather simply
for the purpose of presentation, these are referred to as “state-
ments”. For these statements, it is not possible to indicate evi-
dence levels.
1.6 Consensus strength
As part of a structured consensus agreement process (S2k/S3 lev-
el), the eligible participants at the meeting agree on the state-
ments and recommendations that were drawn up. During this
process, significant modifications to the wording may occur. Sub-
sequently, the consensus strength is determined based on the
number of participants (l" Table 3).1.7 Expert consensus
As the name suggests, “expert consensus” refers to consensus de-
cision specifically for recommendations/statements without a
prior systematic literature search (S2k) or based on the missing
evidence (S2e/S3). The term “expert consensus (EC)” to be used
is synonymous with terms from other guidelines such as “good
clinical practice (GCP)” or “clinical consensus point (CCP)”. The
recommendation strength is graded similarly to the aforemen-
tioned classification without the use of the symbols and is ex-
pressed in purely semantic terms (“must”/“must not” or
“should”/“should not” or “may”/“does not need to”).
2 Introduction
All of the sections below are excerpts from the long version of the
guideline and do not claim to be complete. Only the sections of
the long version are mentioned that contain consensus- and/or
evidence-based statements or recommendations. Sections with-
out these particulars are described briefly at most.
To obtain more information (background texts, additional litera-
ture citations) on existing sections or sections not listed here,
please download the long version (see Guideline documents).
3 Indications and contraindications
3.1 Indications
Common indications for performing hysterectomy for benign
diseases include the following: uterine fibroids, menstrual disor-
ders, adenomyosis of the uterus, endometriosis, uterine prolapse
and precancerous lesions of the endometrium and the cervix.
The numbers in Germany were as follows in 2012: uterine fib-
roids: 60.7%, prolapse: 27.9%, menstrual problems: 25.2%, hy-
perplasia and atypia of the endometrium or cervix: 2.9, and en-
dometriosis: 15.1% of cases [1].Neis KJ et al. Indications and Route… Geburtsh Frauenheilk 2016; 76: 350–364
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also reflects clinical reality, in which the histologically ascertain-
able findings of uterine fibroids, adenomyosis and endometriosis
often coincide. The clinical picture of “menstrual problems” as an
umbrella term encompasses hypermenorrhea, dysmenorrhea
and dyspareunia. For this reason, it is often difficult to list and
code a single diagnosis as the indication for hysterectomy. This
overlapping also means that experts may disagree about the
treatment plan to be used in a particular case. Thus, when indi-
cating surgery for these conditions, personal experience, espe-
cially the mastery of a certain surgical technique or with the use
of alternatives, plays a significantly greater role than for cancer,
for example, for which treatment is based on a single hard diag-
nosis.
Due to this special situation, it is particular important to inform
the patient about the range of treatment options, about the rec-
ommended procedure, the associated risks and to clearly point
out the advantages and disadvantages of each surgical technique
that can be expected and if the merits of techniques “compete
with” each other.
Ultimately, the decision as to whether hysterectomy is indicated,
as well as on using alternative methods, must be made by an in-
formed patient along with her attending physician. For this rea-
son, the term “informed consent and shared decision-making”
has become established.
3.2 Hysterectomy for uterine fibroids
Consensus-based recommendation 3.E1
For suspected symptomatic uterine fibroids, the first step is to
clarify whether the symptoms are actually caused by uterine
fibroids. (expert consensus)
Consensus strength (+++)
Consensus-based recommendation 3.E2
If the symptoms are caused by fibroids, depending on the pa-
tientʼs life circumstances, the treatment decision must be made
together with the patient. (expert consensus)
Consensus strength (+++)
Consensus-based recommendation 3.E3
Hysterectomy may be performed in the case of symptomatic
uterine fibroids, if fertility is no longer desired, if treatment alter-
natives have failed and/or as requested by the patient. (expert
consensus)
Consensus strength (+++)
Evidence-based statement 3.S1
For preoperatively anemic patients with uterine fibroids, drug
therapy with GnRH analogues or Ulipristal may be indicated
prior to hysterectomy. (LoEOxford 2009 1a [GnRH analogues], 1b
[Ulipristal])
Consensus strength (+++)
Literature: GnRH analogues [2,3] and Ulipristal [4,5]
3.3 Dysfunctional uterine bleeding
Consensus-based recommendation 3.E4
For abnormal uterine bleeding, premalignant or malignant le-
sions must be excluded prior to further treatment. (expert con-
sensus)
Consensus strength (+++)Neis KJ et al. Indications and Route… Geburtsh Frauenheilk 2016; 76: 350–364Evidence-based statement 3.S2
If hormone therapy has failed and fertility is no longer desired,
endometrial ablation and hysterectomy is a treatment option.
(LoEOxford 2009 1a)
Consensus strength (+++)
Literature: [6]
Consensus-based recommendation 3.E5
If endometrial ablation has failed, a hysterectomy must be per-
formed. (expert consensus)
Consensus strength (+++)
3.4 Endometriosis/adenomyosis
Evidence-based recommendation 3.E6
To confirm the diagnosis of adenomyosis/endometriosis, a de-
tailed history and an ultrasound examination should be per-
formed. (LoEOxford 2009 1b, GR A)
Consensus strength (+++)
Literature: [7]
Consensus-based recommendation 3.E7
For suspected endometriosis, laparoscopy should also be per-
formed. (expert consensus)
Consensus strength (+++)
Literature: Expert consensus based on S2k Guideline for the Diag-
nosis and Treatment of Endometriosis [8]
Consensus-based recommendation 3.E8
If the primary desire to have a hysterectomy stems from the pa-
tient herself, she must receive detailed information about treat-
ment alternatives and their side effects and success rates. (expert
consensus)
Consensus strength (+++)
Consensus-based recommendation 3.E9
If hormone therapy has failed and fertility is no longer desired, a
hysterectomy should be performed. (expert consensus)
Consensus strength (+++)
Consensus-based statement 3.S3
For deep infiltrating endometriosis, a hysterectomy may be indi-
cated in the overall concept of complete resection. (expert con-
sensus)
Consensus strength (+++)
Literature: Expert consensus based on S2k Guideline for the Diag-
nosis and Treatment of Endometriosis [8]
3.5 and 3.6 Cytological suspicion of endometrial
and glandular precancers
Consensus-based recommendation 3.E10
Microscopically confirmed CIN alone, regardless of severity, is not
an indication for hysterectomy.
In the case of persistent HPV detection after conization alone,
hysterectomy must not be performed.
If there is a cytological or microscopic diagnosis of an adenocarci-
noma in situ (AIS) of the cervix, conization with endocervical cu-
rettage of the high cervical canal must be performed (not a pri-
mary hysterectomy) in order to rule out an invasive adenocarci-
noma.
355GuidelineIf there is a cytological or microscopic diagnosis of an adenocarci-
noma in situ (AIS) of the cervix, a primary hysterectomymust not
be performed in order to rule out an invasive adenocarcinoma.
Instead, conizationwith endocervical curettage of the high cervi-
cal canal must be performed.
Hysterectomy may be performed after conization in the case of
residual recurrent CIN 2/3 or glandular neoplasia located in the
low cervical canal. (expert consensus)
Consensus strength (+++)
Literature: These recommendations were adopted in the expert
consensus based on the S2 Guidelines for HPV infection/pre-inva-
sive lesions of the female genitals: Prevention, Diagnosis and
Treatment [9].
3.7 Atypical endometrial hyperplasia in the histology
of the aspiration or of the curettage material
Consensus-based recommendation 3.E11
For atypical endometrial hyperplasia in women no longer desir-
ing fertility, hysterectomy must be performed. (expert consen-
sus)
Consensus strength (+++)
3.8 Prolapse
Consensus-based statement 3.S4
The uterus may be retained during surgery for uterine prolapse.
(expert consensus)
Consensus strength (+++)
Literature: Expert consensus based on the Guidelines for diag-
nosing and treating uterine prolapse [10]
Consensus-based recommendation 3.E12
If the uterus is retained, the presence of a malignant tumor
should be excluded. (expert consensus)
Consensus strength (+++)
3.9 Urinary incontinence and hysterectomy
Evidence-based recommendation 3.E13
Hysterectomy for incontinence problems must be separately in-
dicated. (LoEOxford 2009 2–3, GR A)
Consensus strength (+++)
Literature: [11]
3.10 Infections
Consensus-based statement 3.S5
To treat an infectious disease of the internal genitals, hysterec-
tomy may be indicated in certain circumstances. (expert consen-
sus)
Consensus strength (+++)
3.11 Chronic pelvic pain
Consensus-based recommendation 3.E14
Laparoscopy should be performed before performing a hysterec-
tomy for chronic pelvic pain. (expert consensus)
Consensus strength (++)
Literature: Expert consensus based on the Guidelines for diag-
nosing chronic pelvic pain in women [12]Evidence-based recommendation 3.E15
When indicating hysterectomy for chronic pelvic pain, the deci-
sion must be made in cooperation with the patient based on in-
terdisciplinary findings and the patient must be informed about
the high failure rate. (LoEOxford 2009 2a−, GR A)
Consensus strength (++)
Literature: [13,14]
3.12 Elective hysterectomy
Consensus-based recommendation 3.E16
A hysterectomy that is not medically indicated to be undertaken
only at the patientʼs request should not be performed. (expert
consensus)
Consensus strength (+++)
3.13 Emergency hysterectomy (nonpuerperal)
Consensus-based statement 3.S6
In rare cases, a nonpuerperal emergency hysterectomy is indi-
cated (trauma, coagulation disorder, bleeding, infection). (expert
consensus)
Consensus strength (++)
4 Alternatives to hysterectomy
4.1 Uterine fibroids
When choosing an alternative to hysterectomy, the effectiveness
and safety of the selected treatment method and the risk of fi-
broid recurrence should be weighed against the (potential) ad-
vantages of retaining the uterus (lower morbidity and retained
fertility). In the end, rare complications may necessitate the ac-
tually unwanted hysterectomy [15].
Consensus-based recommendation 4.E17
Patients must be informed about the individual success and fail-
ure rates related to the various methods of fibroid treatment. (ex-
pert consensus)
Consensus strength (+++)
4.2 Menstrual disorders
A number of reasons are responsible for menstrual disorders.
Around 50% of menstrual disorders have organic causes. These
cases require causal treatment such as hysteroscopic polyp and
fibroid resection (see also Uterine fibroids) or treatment of ad-
enomyosis or endometrial hyperplasia. If organic causes have
been ruled out, intermenstrual and dysfunctional bleeding can
generally be treated with hormones, primarily progestogens,
and in some cases, also estrogens. The primary indications for
hysterectomy are refractory hypermenorrhea and menorrhagia.
Before resorting to hysterectomy, the patient should receive in-
depth information about the wide range of proven alternatives.
Evidence-based recommendation 4.E18
Patients must be informed about the individual success and fail-
ure rates related to the various methods of menstrual disorder
treatment. (LoEOxford 2009 1b [LNG-IUS], 1a [endometrial ablation],
GR A)
Consensus strength (+++)
Literature: LNG‑IUS [16,17] and endometrial ablation [18]Neis KJ et al. Indications and Route… Geburtsh Frauenheilk 2016; 76: 350–364
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Preoperative information and consent includes the following:
" the indication and objective of the procedure including an as-
sessment of the probability of success
" presentation of options for treatment/methods, including non-
surgical alternatives
" explanation of the preferred method
" description of procedure-related risks and typical complica-
tions, including their sequelae
" information about patient behavior before and after the proce-
dure.
Consensus-based statement 5.S7
The nature, scope, time and form of information and consent are
based on the patientʼs individual situation, the legal provisions
and current case rulings. Treatment options, side effects and
probability of success must be presented. (expert consensus)
Consensus strength (+++)
6 Perioperative management
Hysterectomy is a procedure that generally involves the same
steps regardless of the indication. For this reason, for quality-re-
lated (and forensic) reasons, every hospital is advised to develop
standards for perioperative management based on the current
evidence. Perioperative checklists are recommended to prevent
errors and ensure patient safety [19–24].
6.1 Preoperative management
Consensus-based recommendation 5.E19
For patients with known or suspected organic or systemic disor-
ders, the relevant laboratory parameters (e.g. for patients with
bleeding disorders) must be determined. (expert consensus)
Consensus strength (+++)
6.2 Intraoperative management
Evidence-based recommendation 6.E20
Prophylactic antibiotics must be administered prior to hysterec-
tomy. (LoEOxford 2009 1a, GR A)
Consensus strength (+++)
Literature: [25]
6.3 Postoperative management
Evidence-based recommendation 6.E21
Perioperatively, risk-adapted thromboembolic prophylaxis must
be administered. (LoEOxford 2009 1a, GR A)
Consensus strength (+++)
Literature: [26]
7 Surgical techniques
7.1 Vaginal hysterectomy
In addition to the general indication for a hysterectomy, the use
of a vaginal approach involves the following special aspects:
" To ensure that the approach is reliable, the uterus must be suf-
ficiently mobile. In general, with the patient under anesthesia,
it should be possible to pull the portio to at least the mid-vagi-
na. The vagina must be sufficiently broad and elastic for the
surgery to be performed safely. In case of doubt, it may be help-
ful to perform the pelvic examination under anesthesia by
pulling on the portio using bullet forceps.
" In the case of suspected extrauterine pathology prior to sur-
gery, for instance, in the adnexa, a laparoscopically assisted or
abdominal approach should be favored.Neis KJ et al. Indications and Route… Geburtsh Frauenheilk 2016; 76: 350–364" A vaginal approach is therefore particularly suitable for benign
uterine diseases such as uterine prolapse. For nulliparous
women and postmenopausal patients with atrophied vaginas
and patients with long, narrow vaginas (obese patients) and
patients with massively enlarged uteruses, the vaginal ap-
proach has its limits.
" However, the size of the uterus can be overcome by using mor-
cellation or hemisection. As a rule of thumb, again depending
on the sufficient breadth of access and the mobility of the or-
gan, vaginal hysterectomy can be performed for a uterine size
of around a 12-week pregnancy or a uterine weight of around
250 to 300 g. This corresponds to an average diameter of the
uterine body of around 8 to 10 cm [27]. On the other hand,
much larger uteruses can also be delivered safely using a vagi-
nal approach [28].
" If a patient has already had a Cesarean section or undergone
other pelvic surgery, vaginal hysterectomy can be much more
difficult and the risk of injuring the bladder is increased. In this
case, the situationmust be taken into considerationwhen indi-
cating vaginal hysterectomy.
" In the case of suspected or confirmed uterine or ovarian malig-
nancy, a purely vaginal procedure should not be the primary
choice. Selected patients with microinvasive cervical cancer or
endometrial cancer are exceptions [29].
7.2 Laparoscopically assisted vaginal hysterectomy
(LAVH)
Laparoscopically assisted vaginal hysterectomy (LAVH) combines
laparoscopic and vaginal surgical techniques. The use of laparos-
copy intends to avoid abdominal hysterectomy and enable vagi-
nal hysterectomy. The laparoscopic part of the procedure in-
cludes all of the steps that cannot be performed vaginally or that
can only be performed with a great deal of difficulty or increased
risk (adhesiolysis, excision of endometriotic nodules, adenec-
tomy, detachment of the adnexa from the uterus). During LAVH,
dissection in the area of the broad ligament of the uterus and the
parametria ends above the uterine artery, which is detached
from the vaginal side.
The uterus is extracted through the vagina and if needed, hemi-
otomy or morcellation is carried out.
No specific contraindications applying only to LAVH are known. If
laparoscopy is contraindicated in general, a purely vaginal or ab-
dominal approach must be considered.
7.3 Total laparoscopic hysterectomy (TLH)
With total laparoscopic hysterectomy (TLH), all steps of the pro-
cedure are performed laparoscopically. In contrast to LAVH, the
dissection of the uterine artery is performed laparoscopically, as
is the paracervical dissection up to the vagina, the detachment of
the uterus from the vagina and the closure of the vagina by
means of laparoscopic suturing. There is no switch from an ab-
dominal to a vaginal approach. Due to the dissection, in particular
in the area of the cervix, TLH must be learned as a separate surgi-
cal procedure, even by surgeons with laparoscopic experience
[30]. For this reason, systematic reviews [31] report about ele-
vated rates of complications, especially in the area of the urogen-
ital tract, as well as increased risk of bleeding and relatively long
operation times and recommend that this surgical procedure
should be considered as a secondary choice. However, at centers
with extensive TLH experience these problems have largely been
resolved [30,32]. Therefore, if there is sufficient experience with
the technique, its complication rate is similar to that of other lap-
357Guidelinearoscopic surgical procedures. It appears that the operating time
is longer than the operating time for vaginal hysterectomy and
LAVH [31]. This is confirmed by the metaanalysis conducted by
Gendy et al. [33]. However, the metaanalysis also confirmed that
with the inclusion of 5 randomized controlled trials (RCTs) there
were no differences with respect to complication rates (LoE 2a,
level decreased due to high heterogeneity of the study results
and signs of publication bias).
Several publications report postoperative dehiscences of the
vaginal cuff in contrast to other modes of hysterectomy [34–36].
This is attributed to the high frequency surgical detachment of
the uterus from the vagina, whereby the endoscopic suturing
technique is also discussed. A randomized study of vaginal stump
suturing techniques comparing vaginal and laparoscopic ap-
proaches by an experienced surgeon did not yield any differences
[37].
7.4 Laparoscopic supracervical hysterectomy (LASH)
LASH constitutes an alternative to abdominal, total vaginal and
total laparoscopic hysterectomy. In 2010, supracervical hysterec-
tomy was performed in 13.5% of cases in Germany, most of them
using a laparoscopic approach [1]. In the United States, 2% of all
hysterectomies are performed supracervically, while in Scandi-
navia, around 36% of all hysterectomies are performed as supra-
cervical hysterectomies [38].
With LASH, the first steps are performed similar to the procedure
for LAVH and TLH and involve exposure of the site and dissection
of possible associated pathologies (adhesions, endometriosis, ad-
nexal abnormalities). Laparoscopic dissection ends at the level of
the uterovesical fold. The uterus is detached supracervically and
after intraabdominal morcellation is removed via the trocar.
LASH is a procedure with a low complication rate [39–41]. De-
taching the uterine body from the cervix at the level of the isth-
mus means that surgery in the area of the parametria and dissec-
tion of the bladder is required to only a limited extent, if at all.
The complications reported for TLH, such as urinary tract lesions
or dissection-related bleeding, are therefore rare for LASH.7.5 Abdominal hysterectomy
In addition to the general indication for a hysterectomy, the use
of the abdominal approach involves the following special aspects:
" In addition to oncological indications, the size of the uterus and
associated disorders such as endometriosis or extensive adhe-
sions resulting from previous surgery are indications for ab-
dominal hysterectomy.
" An abdominal approach is also indicated depending on the in-
dividual situation in patients with a long, narrow vagina, for
nulliparous women and patients with comorbidities and in pa-
tients for whom a vaginal or laparoscopic approach does not
appear to be possible or would be associated with an increased
complication risk. In case of doubt, when deciding whether ab-
dominal hysterectomy is indicated, it may be helpful to per-
form the pelvic examination under anesthesia by pulling on
the portio using bullet forceps.
7.6 Robot-assisted hysterectomy
Robot-assisted surgical procedures are used to a limited extent
for treating gynecological and obstetrics patients. They are often
indicated in patients with cancer. Robot-assisted hysterectomy
can be implemented and can be performed quickly by a surgeon
with laparoscopic experience [42,43]. Since the expenses and the
operating time are far greater than those for conventional lapa-
roscopy, in view of the limited resources, the use of robot-assis-
ted hysterectomy must be decided on a case-by-case basis [44–
47]. Systematic overview articles on robot-assisted hysterectomy
(Tapper et al. 2014 [48], Liu et al. 2012 [49], Liu et al. 2014 [50])
identified the same 2 RCTs (Paraiso et al. 2013 [51], Sarlos et al.
2010 [46] [LoE 1b]). The interpretation of both RCTs showed dif-
ferences in operating times. No differences were observed with
regard to complications (blood loss, “minor” or “major” compli-
cations or postoperative use of pain medication).
With regard to quality of life, Sarlos et al. –without blinding – ob-
served improvements in some aspects of quality of life after 3
weeks and after 6 to 8 weeks, while Paraiso et al. did not observe
any differences after 6 months. In both studies, the operating
time for robot-assisted hysterectomy was significantly longer
than for laparoscopic surgery, with Paraiso observing an average
longer time of 70 minutes and Sarlos reporting 20 minutes lon-
ger. The length of hospital stay did not differ.
A systematic review of robot-assisted hysterectomy with a single
site port [52] found only retrospective series or case studies with
a median operating time of 109 minutes. No information on
transfusions was reported (LoE 3). No information on complica-
tions or follow-upwas reported. The procedure must still be con-
sidered to be experimental.Neis KJ et al. Indications and Route… Geburtsh Frauenheilk 2016; 76: 350–364
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(l" Table 4)Table 4 Incidence of intraoperative and postoperative complications.
FINHYST 2011 (complication) n = 5279 (%) AQUA 2012 (complication) n = 103232 (%)
Intraoperative blood loss ≥ 1000ml AH
LH
VH
5.7
3.0
1.6
Intraoperative blood loss ≥ 1000ml No comparative data
Bladder injury AH
LH
VH
0.9
1.0
0.6
Bladder injury 0.59
Ureter injury AH
LH
VH
0.3
0.3
0.04
Ureter injury 0.09
Bowel injury AH
LH
VH
0.2
0.4
0.1
Bowel injury 0.23
Postoperative bleeding or hematoma AH
LH
VH
2.6
2.7
2.8
Postoperative bleeding or hematoma 0.94
Ileus AH
LH
VH
1.0
0.3
0.1
Ileus 0.09
Urinary retention AH
LH
VH
0.5
0.5
1.6
Urinary retention No comparable data
Urinary tract infection AH
LH
VH
2.2
0.7
1.5
Urinary tract infection 1.0
Wound infection AH
LH
VH
2.4
1.5
0.9
Wound infection No comparable data
Febrile events AH
LH
VH
2.5
1.4
0.9
Febrile events 0.28
Pelvic infection, hematoma or abscess 10
54
51
1.00
5.08
5.40
Pelvic infection, hematoma or ab-
scess
No comparable data
FINHYSTstudy: n = 5279 with 1255 abdominal, 1679 laparoscopic and 2345 vaginal hysterectomies in Finland in 2006 [53]; AQUA 2012: n = 103232 independent of approach and
distinction between endoscopically performed hysterectomies, only exact mention of 16196 abdominal hysterectomies and 57398 vaginal hysterectomies.
Abbreviations: AH = abdominal hysterectomy, LH = laparoscopic hysterectomy, VH = vaginal hysterectomy9 Documentation
Every patient chart created for a patient undergoing a hysterec-
tomymust include the indication, the symptoms and the findings
of the patient. These comprise the general and specific history,
especially previous illnesses and operations, as well as the gener-
al and gynecological examination results including imaging re-
sults.
Checklists have proven helpful for perioperative documentation.
The surgical report lists the date, diagnosis and summary of the
treatment plan, along with the names of the physicians involved.
The surgical report serves as a description of the surgical proce-
dure and the findings observed during surgery. In the case of an
uncomplicated hysterectomy, this description may be brief. A
surgical report becomes particularly important, however, if com-
plications occur. It is recommended to clearly describe in the pri-
mary report any special anatomic circumstances and other con-
ditions giving rise to complications. At critical points, such as in
the case of parametric bleeding, the surgeon should state that
he or she checked the ureter by means of inspection, palpation
or exposure and acted properly and carefully.Neis KJ et al. Indications and Route… Geburtsh Frauenheilk 2016; 76: 350–364The postoperative course must also be documented. The scope
and results of a physical examination should be listed in the form
of notes accompanied by the time of day. The same procedure
should be used for findings from other hospitals and institutes.
The discharge summary is also very important.
10 Comparison of methods
In recent years, numerous publications and two systematic re-
views have compared methods. The recommendation of the Na-
tional Institute for Health and Care Excellence (NICE) [54] was
first drawn up in 2002 and was adapted in 2004 and 2006. Inde-
pendent of this recommendation, a Cochrane Review was con-
ducted and published in 2009 [31], LoE 1a. For the most part,
the reviews examine the same studies. Nieboer et al. recently
evaluated 34 studies with a total of 4495 women. The NICE pub-
lication also evaluated a control study with 37049 women and a
control study with 10100 women.
The advantages of vaginal hysterectomy compared to abdominal
hysterectomy involved the significantly shorter recovery time
(mean difference [MD] 9.5 days), fewer febrile episodes and un-
specific infections (OR 0.42) and shorter hospital stays (MD 1.1
Table 5 Comparison of hysterectomy methods
Vaginal hysterectomy vs. abdominal hysterectomy
Quicker return to normal activity Average difference 9.5 days
Fewer febrile events, fewer febrile
episodes and specific infections
OR 0.42; CI 0.21–0.83
Shorter hospital stay Average difference 1.1 days
LH vs. abdominal hysterectomy
Return to normal activity Average difference 13.6 days
Lower blood loss Average 45 cm3
Lower drop in HB Average difference 0.55 g/dl
Shorter hospital stay Average difference 2.0 days
Less wound and abdominal infiltrates OR 0.31; CI 0.12–0.77
More bladder and ureter injuries OR 2.41; CI 1.21–4.82
Longer operating time Average 2.3min
LAVH vs. TLH
Lower rate of infection OR 3.77; CI 1.05–13.51
Shorting operating time Average 25.3min
VH vs. LH
Shorter operating time Average 39.3min
Less intraoperative bleeding OR 2.76; CI 1.02–7.42
359Guidelinedays). When comparing vaginal hysterectomy with laparoscopic
hysterectomy (LH), no significant differences were found in this
respect. However the operating time was longer for LH (MD 39.3
minutes) and severe bleeding occurred more frequently (OR
2.76). The Cochrane Review concluded that owing to the same
or significantly more favorable results across the board, vaginal
hysterectomy should be preferred over abdominal hysterectomy
whenever possible. If a vaginal hysterectomy is not possible, lap-
aroscopic procedures can be used to avoid the disadvantages of a
laparotomy due to the more favorable adverse effect profile [27].
The American College of Obstetricians and Gynecologists came
up with the same recommendations [55].
Diverse comparative analyses have come up with identical re-
sults for the procedure with the lowest costs, which is vaginal
hysterectomy.
In addition to the systematic review by Nieboer et al., after updat-
ing the search to include publications up to June 2014, other sys-
tematic overview articles were included on the following issues
related to the comparison of methods (l" Tables 5 und 6):Table 6 Comparison of different hysterectomy modalities.
Operating time Blood loss Complications Admission period Return to work Costs
Vaginal hysterectomy +++ +++ +++ +++ +++ +++
LAVH ++ +++ +++ +++ +++ ++
TLH ++ ++(+) ++(+) +++ +++ ++
LASH ++ +++ +++ +++ +++ ++
Abdominal HE ++ ++ ++ + + ++
Number of “+”means increasing advantage of the method.Evidence-based recommendation 10.E22
If possible, vaginal hysterectomymust be favored over abdominal
hysterectomy. (LoEOxford 2009 1a, GR A)
Consensus strength (+++)
Literature: [42,56,57]
Evidence-based recommendation 10.E23
If vaginal hysterectomy is not possible, the possibility of laparo-
scopic hysterectomy should be reviewed. (LoEOxford 2009 1a, GR B)
Consensus strength (+++)
Literature: [42,58]
Evidence-based recommendation 10.E24
LASHmay be performed as an alternative to abdominal hysterec-
tomy and vaginal hysterectomy. (LoEOxford 2009 1a, GR 0)
Consensus strength (+++)
Literature: [59]
Consensus-based statement 10.S8
However, current data do not permit the different laparoscopic
techniques to be exactly differentiated. (expert consensus)
Consensus strength (+++)Consensus-based recommendation 10.E25
Abdominal hysterectomy should only be performed if it is specif-
ically indicated. (expert consensus)
Consensus strength (+++)
Evidence-based statement 10.S9
In the available randomized studies, no confirmed patient-
related benefits were found for the use of robot-assisted technol-
ogy. (LoEOxford 2009 1b)
Literature: [45–47]
11 Special situation –What do I do if…?
11.1 Hysterectomy for adenomyosis/endometriosis
Consensus-based recommendation 11.E26
If the patient has the relevant symptoms, there is no desire for
fertility and there are clinical signs of adenomyosis, a hysterec-
tomy should be performed. (expert consensus)
Consensus strength (+++)
Consensus-based statement 11.S10
For deep infiltrating endometriosis, a hysterectomy may be indi-
cated in the overall concept of complete resection. (expert con-
sensus)
Consensus strength (+++)Neis KJ et al. Indications and Route… Geburtsh Frauenheilk 2016; 76: 350–364
360 GebFra Science11.2 Hysterectomy and incontinence
If a patient for whom a hysterectomy is indicated is to undergo
surgery for stress incontinence at the same time, the hysterec-
tomy may be performed using the most straightforward proce-
dure. The stress incontinence surgery does not impact the meth-
od used for hysterectomy.
11.3 Obstetric hysterectomy for postpartum
hemorrhage
Consensus-based recommendation 11.E27
For postpartum, life-threatening uterine bleeding and the failure
of alternative treatment options, a hysterectomy is indicated as a
last resort and in the event of a life-threatening situation. (expert
consensus)
Consensus strength (+++)Uterine fi
Discontinue t
Sympto
Fertility no long
Patient wou
HysterecUterine artery embolization (UAE)
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Yes
Fig. 1 Pathway: Uterine fibroids.
Neis KJ et al. Indications and Route… Geburtsh Frauenheilk 2016; 76: 350–36412 Quality of life
Evidence-based recommendation 12.E28
Patients should be informed that after they have undergone an
indicated hysterectomy, they can generally expect to experience
improvement in quality of life and sexual functioning compared
to their preoperative situation. (LoEOxford 2009 1a, GR B)
Literature: [60–63]
Evidence-based statement 12.S11
A prophylactic bilateral adnexectomymay be associatedwith un-
desired long-term adverse effects and requires separate informa-
tion and consent. (LoEOxford 2009 1a)
Consensus strength (++)
Literature: [64,65]
13 Algorithm: Alternatives to hysterectomy
(l" Figs. 1 to 3)broids
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